6533b823fe1ef96bd127e2e3
RESEARCH PRODUCT
Tumor vaccination using messenger RNA: prospects of a future therapy.
Ugur SahinÖZlem TüreciAbderraouf SelmiMustafa DikenSebastian Kreitersubject
Messenger RNAClinical Trials as TopicImmunologyRNACancerDendritic CellsBiologyAdaptive Immunitymedicine.diseaseAcquired immune systemCancer VaccinesVaccinationSafety profileImmune systemAntigenNeoplasmsImmunologymedicineImmunology and AllergyAnimalsHumansRNA Messengerdescription
While the endeavor to vaccinate against cancer has been pursued for over 20 years, only recently was the first tumor vaccine approved. Among the different antigen formats assessed for vaccination, coding messenger RNA (mRNA) is emerging as a particularly attractive option. It can code for all types of transcript based proteins, is easy and cost efficient to produce, has a favorable safety profile and enables induction of combined immune responses. Within the last few years major developments have been achieved in this field. Clinical approaches use mRNA either for direct administration or for engineering of adoptively transferred dendritic cells. However, there are still challenges to be overcome for successful clinical application of mRNA-based immunotherapies.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2011-06-01 | Current opinion in immunology |